Predictors of complications following alloplastic cranioplasty in trauma patients: A multi-center retrospective study
PLOS One · 2025
DOI: 10.1371/journal.pone.0321870 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift PLOS One, 2025. Verfasst von Jingguo Yang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan province, PR China. Hauptthemen laut MEDLINE: Decompressive Craniectomy, Postoperative Complications, Plastic Surgery Procedures. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Object Although technically simple, cranioplasty following decompressive craniectomy is associated with high complication rates. Assessing the factors that contribute to these complications is essential. The study aimed to present the complications following alloplastic cranioplasty in trauma patients and evaluate the factors that predispose patients to an increased risk of complications.
Methods
The author retrospectively reviewed cranioplasty cases at three institutions following craniectomy for trauma between 01/01/2018 and 31/12/2021. The risk factors included age, sex, smoking history, defect site, defect size, type of alloplastic materials, hydrocephalus after decompressive craniectomy (DC), hydrocephalus shunts before cranioplasty (CP), and the time interval between initial craniectomy and cranioplasty. The cranioplasty complications assessed were postoperative new-onset seizures, reoperation for hematoma, implant failure, and postoperative subgaleal effusion. Multivariate logistic regression analysis was performed to assess these risk factors.
Results
A total of 191 cranioplasties were included in this study, with a major complication rate of 26.2% (50 of 191). In multivariate analysis, the risk factors for major complications were smoking history, titanium cranioplasty, and a time interval to cranioplasty exceeding 3 months. Predictors of new-onset seizures in multivariate analysis included younger age, smoking history (OR = 4.69, p < 0.001), titanium cranioplasty (OR = 4.85, p = 0.049), and intermediate CP (OR = 5.46, p = 0.042). The rates of implant failure and postoperative hematoma were higher when cranioplasty was performed over 3 months or involved titanium cranioplasty. The rate of minor complication, specifically subgaleal effusion, was 18.9% (36 cases), with male sex being a significant variable in multivariate analysis.
Conclusions
This study presented complications and predictors of complications for cranioplasty in trauma patients, which could be incorporated with surgical decision-making for neurosurgeons.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, Sichuan province, PR China.
ORCID-Profile: Junwen Guan
Förderung
- 1·3·5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University
- National Natural Science Foundation of China
Zitieren
APA
Yang, J., Wang, J., You, C., Ma, L., & Guan, J. (2025). Predictors of complications following alloplastic cranioplasty in trauma patients: A multi-center retrospective study. PLOS One. https://doi.org/10.1371/journal.pone.0321870
Vancouver
Yang J, Wang J, You C, Ma L, Guan J. Predictors of complications following alloplastic cranioplasty in trauma patients: A multi-center retrospective study. PLOS One. 2025. doi:10.1371/journal.pone.0321870
BibTeX
@article{Yang2025,
author = {Yang, Jingguo and Wang, Junjie and You, Chao and Ma, Lu and Guan, Junwen},
title = {Predictors of complications following alloplastic cranioplasty in trauma patients: A multi-center retrospective study},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321870}
}
EUVIMED